Fuzeon Increased Pneumonia Incidence Likely A "Specious" Finding – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The increased incidence of bacterial pneumonia seen with Roche/Trimeris’ Fuzeon may be an artifact of the design of the pivotal trails, FDA suggested in review documents for the HIV therapy.
You may also be interested in...
Tibotec Prezista Mortality Imbalance Due To Partially Blinded Trials – FDA Review
FDA officials called the lack of deaths in the control arms of Tibotec’s Prezista trials "striking" and "out of the range of past experience," and attributed the anomaly to the partially blinded study design.
Fuzeon Sales Message: All Patients Benefit, But "The Earlier The Better"
Roche is emphasizing the benefit of early administration of its HIV therapy Fuzeon.
Fuzeon Discontinuations From Injection Reactions Remain Low At 48 Weeks
Roche/Trimeris’ 48-week follow-up data for Fuzeon show a continued low rate of discontinuation due to injection site reactions.